Synchronous Bilateral Breast Cancer: Clinical Features, Pathology and Survival Outcomes from a Tertiary Cancer Center

  • Priya Iyer
  • Venkatraman Radhakrishnan
  • Balasubramanian Ananthi
  • Ganesarajah Selvaluxmy
  • V Sridevi
Original Article



Synchronous bilateral breast cancers (SBBCs) are rare and are defined as occurrence of tumor in the contralateral breast within 6 months of diagnosis of the primary breast tumor. The present study was conducted to look at the clinical and pathological profile and outcomes of patients with SBBC at our center.

Materials and Methods

All SBBC patients treated at our center between 2001 and 2015 were enrolled in the study. Data were retrospectively extracted from the patient case record.


The study included 55 patients with SBBC with a median age of 52 years. Mammographically detected contralateral breast tumor constituted 7% of the cases. The maximum stage in either breast was stage II in 8/55 (15%) patients, stage III in 37/55 (67%) and stage IV in 10/55 (18%). Infiltrating ductal adenocarcinoma (IDC) was the most common pathology and was concordant in both the breasts in 53/55 (96%) patients. Concordance for estrogen receptor (ER), progesterone receptor (PR) and Her2 receptor was seen in 85, 89 and 92%, respectively. The 3-year event-free survival and overall survival for stages II, III and IV were 100, 61 and 0% (P < 0.001) and 100, 64.5 and 0% (P < 0.001), respectively.


SBBC patients at our center present in advanced stage. The maximum stage of either breast tumor determines the outcome. There is heterogeneity in the clinical features, pathological features and survival outcome of SBBC reported from India and rest of the world.


Synchronous breast cancer Chemotherapy Radiotherapy Surgery 


Compliance with Ethical Standards


The study had no source of funding.

Conflict of interest

None of the authors have any conflict of interest.

Ethical Approval

The study is retrospective in nature. For this type of study, formal consent and ethical approval are not required. This article does not contain any studies with animals performed by any of the authors.

Informed Consent

The study is retrospective in nature and does not require informed consent of individual participants included in the study.


  1. 1.
    Londero AP, Bernardi S, Bertozzi S, Angione V, Gentile G, Dri C, et al. Synchronous and metachronous breast malignancies: a cross-sectional retrospective study and review of the literature. Biomed Res Int. 2014;2014:250727.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007;25:4210–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Sathwara J, Bobdey S, Ganesh B. Breast cancer survival studies in India: a review. Int J Res Med Sci. 2016;4:3102–8.CrossRefGoogle Scholar
  4. 4.
    Agarwal G, Ramakant P. Breast cancer care in India: the current scenario and the challenges for the future. Breast Care (Basel). 2008;3:21–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chen JJ, Wang Y, Xue JY, Chen Y, Chen YL, Xiao Q, et al. A clinicopathological study of early-stage synchronous bilateral breast cancer: a retrospective evaluation and prospective validation of potential risk factors. PLoS ONE. 2014;9:e95185.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Selvakumar VP, Garg S, Siddiqui K, Goel A, Kumar K, Kumar R. Tailored approach to management of bilateral breast cancer in Indian women. Asian J Oncol. 2015;1:97–100.CrossRefGoogle Scholar
  7. 7.
    Krishnappa R, Chikaraddi SB, Deshmane V. Primary synchronous bilateral breast cancer. Indian J Cancer. 2014;51:256–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Padmanabhan N, Subramanyan A, Radhakrishna S. Synchronous bilateral breast cancers. J Clin Diagn Res. 2015;9:XC05–8.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Gogia A, Raina V, Deo SV, Shukla NK, Mohanti BK, Sharma DN. Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience. Asian Pac J Cancer Prev. 2014;15:1989–92.CrossRefPubMedGoogle Scholar
  10. 10.
    Patnayak R, Jena A, Rukmangadha N, Chowhan AK, Sambasivaiah K, Phaneendra BV, et al. Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: a tertiary care center experience. Indian J Med Paediatr Oncol. 2015;36:117–22.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Doval DC, Sharma A, Sinha R, Kumar K, Dewan AK, Chaturvedi H, et al. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in New Delhi, India. Asian Pac J Cancer Prev. 2015;16:4959–64.CrossRefPubMedGoogle Scholar
  12. 12.
    Safal M, Lower EE, Hasselgren PO, Hungness ES, Gazder P, Aron B, et al. Bilateral synchronous breast cancer and HER-2/neu overexpression. Breast Cancer Res Treat. 2002;72:195–201.CrossRefPubMedGoogle Scholar
  13. 13.
    Gong SJ, Rha SY, Jeung HC, Roh JK, Yang WI, Chung HC. Bilateral breast cancer: differential diagnosis using histological and biological parameters. Jpn J Clin Oncol. 2007;37:487–92.CrossRefPubMedGoogle Scholar
  14. 14.
    Saad RS, Denning KL, Finkelstein SD, Liu Y, Pereira TC, Lin X, et al. Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma. Mod Pathol. 2008;21:1200–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Imyanitov EN, Hanson KP. Molecular pathogenesis of bilateral breast cancer. Cancer Lett. 2003;191:1–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Shanta V, Swaminathan R, Rama R, Radhika R. Retrospective analysis of locally advanced noninflammatory breast cancer from Chennai, South India, 1990–1999. Int J Radiat Oncol Biol Phys. 2008;70:51–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Vuoto HD, García AM, Candás GB, Zimmermann AG, Uriburu JL, Isetta JA, et al. Bilateral breast carcinoma: clinical characteristics and its impact on survival. Breast J. 2010;16:625–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Kheirelseid EA, Jumustafa H, Miller N, Curran C, Sweeney K, Malone C, et al. Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Res Treat. 2011;126:131–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Schmid SM, Pfefferkorn C, Myrick ME, Viehl CT, Obermann E, Schötzau A, et al. Prognosis of early-stage synchronous bilateral invasive breast cancer. Eur J Surg Oncol. 2011;37:623–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol. 2002;28:388–91.CrossRefPubMedGoogle Scholar
  21. 21.
    Beckmann KR, Buckingham J, Craft P, Dahlstrom JE, Zhang Y, Roder D, et al. Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort. Breast. 2011;20:158–64.CrossRefPubMedGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2017

Authors and Affiliations

  • Priya Iyer
    • 1
  • Venkatraman Radhakrishnan
    • 2
  • Balasubramanian Ananthi
    • 1
  • Ganesarajah Selvaluxmy
    • 1
  • V Sridevi
    • 3
  1. 1.Department of RadiotherapyCancer Institute (WIA)AdyarIndia
  2. 2.Department of Medical OncologyCancer Institute (WIA)AdyarIndia
  3. 3.Department of Surgical OncologyCancer Institute (WIA)AdyarIndia

Personalised recommendations